A federal judge on Tuesday dismissed, for the second time, a whistleblower lawsuit accusing drugmaker Novartis AG of paying kickbacks to doctors through a sham speaker program to promote its multiple sclerosis drug Gilenya.
https://www.pharmalive.com/wp-content/uploads/2021/12/Novartis-working-on-pan-coronavirus-oral-treatment-CEO-says-Reuters-12-6-21.jpg503960Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-09-13 18:44:322022-09-13 22:38:30Novartis escapes claim that it paid kickbacks to promote MS drug
